Skip to main
SRPT

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Sarepta Therapeutics (SRPT) Analyst Ratings

Based on 25 analyst ratings
Hold
Strong Buy 8%
Buy 28%
Hold 48%
Sell 4%
Strong Sell 12%

Bulls say

Sarepta Therapeutics Inc. exhibits a strong potential for growth, demonstrated by a consistent number of start forms, which management believes could translate into annual sales surpassing the $500 million mark. The preliminary net revenue for PMO products of $259.2 million in Q4 2025 reflects a 9% increase from the previous quarter, indicating stable adoption and resilient payer coverage despite ongoing clinical evaluations. Additionally, anticipated initial data from the Phase 1/2 programs for FSHD and DM1 may further enhance the company’s outlook, as competitive siRNA profiles could foster additional revenue opportunities not currently reflected in valuation models.

Bears say

Sarepta Therapeutics Inc. reported a preliminary fourth quarter 2025 Elevidys net revenue of $110.4 million, which fell short of the $117 million consensus expectation and highlighted revenue volatility, particularly due to the deferral of treatments for six patients. Despite management's optimism regarding an annual sales floor of $500 million and plans to double the salesforce in 2026, concerns linger about the company's reliance on a small patient base, which could significantly impact quarterly revenue figures. Additionally, there are doubts about Elevidys's true efficacy and safety profile in the Duchenne muscular dystrophy population, alongside growing competition from next-generation therapies, which could pressure future demand.

Sarepta Therapeutics (SRPT) has been analyzed by 25 analysts, with a consensus rating of Hold. 8% of analysts recommend a Strong Buy, 28% recommend Buy, 48% suggest Holding, 4% advise Selling, and 12% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sarepta Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sarepta Therapeutics (SRPT) Forecast

Analysts have given Sarepta Therapeutics (SRPT) a Hold based on their latest research and market trends.

According to 25 analysts, Sarepta Therapeutics (SRPT) has a Hold consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sarepta Therapeutics (SRPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.